Edwards Lifesciences (NYSE:EW) VP Annette Bruls Sells 2,644 Shares

Edwards Lifesciences Corporation (NYSE:EW) VP Annette Bruls sold 2,644 shares of Edwards Lifesciences stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the sale, the vice president directly owned 17,984 shares of the company’s stock, valued at $1,618,200.32. This trade represents a 12.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Edwards Lifesciences Trading Up 0.3%

Edwards Lifesciences stock opened at $90.19 on Friday. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The stock has a market cap of $51.93 billion, a P/E ratio of 51.83, a P/E/G ratio of 2.36 and a beta of 0.85. The company’s fifty day simple moving average is $89.54 and its 200-day simple moving average is $85.03.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.Edwards Lifesciences’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period last year, the company earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Institutional Trading of Edwards Lifesciences

Several large investors have recently made changes to their positions in the stock. Brighton Jones LLC bought a new stake in Edwards Lifesciences during the fourth quarter worth approximately $266,000. NewEdge Advisors LLC grew its holdings in Edwards Lifesciences by 8.1% during the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after purchasing an additional 2,665 shares during the last quarter. Sei Investments Co. raised its position in shares of Edwards Lifesciences by 16.7% in the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after purchasing an additional 58,988 shares during the period. Squarepoint Ops LLC raised its position in shares of Edwards Lifesciences by 277.7% in the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock valued at $5,417,000 after purchasing an additional 50,924 shares during the period. Finally, Treasurer of the State of North Carolina lifted its stake in shares of Edwards Lifesciences by 0.4% in the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock worth $21,028,000 after buying an additional 1,065 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on EW. Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Mizuho raised their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Citigroup lifted their target price on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Finally, Royal Bank Of Canada boosted their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.